Annual Securities Report — FY2025
What Cuorips Inc. reported for the period from 2025-04-01 to 2026-03-31.
Filed 2026-06-24View the original on EDINET
How much it says
52Typical
What moved here
26named for the first time
Its own wording
68terms
Which filing this is
9/ 9newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist
The Company has obtained conditional and time-limited marketing approval in Japan for Reheart, its myocardial cell sheet, and has secured its designation as a regenerative medical product for rare diseases. It is preparing the system required for post-marketing surveillance while advancing overseas expansion and development of next-generation pipeline projects, including catheter-based therapy and the YS series. The filing also describes the CDMO business using CLiC-1 and consortium activities focused on large-scale cell culture.
Komori's summary of this document, not the document's own words.52Typical
How much this filing saysA weighted roll-up of 11 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 36 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
96
Very detailed
45
Typical
52
Typical
75
Very detailed
15
Almost nothing
0
Almost nothing
55
Typical
69
Detailed
7
Almost nothing
79
Very detailed
77
Very detailed
R&D spend10億円Money spent making new things.
Cash left over-11億円Cash from the business, less what went into equipment.
Spent on equipment69百万円Plants, machines — things meant to last.
Employees51Headcount at the end of this period.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.